Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III

被引:47
|
作者
Iskandar, Mazen E. [1 ]
Bonomo, Giovanni [1 ]
Avadhani, Vaidehi [2 ]
Persky, Mark [3 ]
Lucido, David [4 ,5 ]
Wang, Beverly [2 ]
Marti, Jennifer L. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Div Endocrine Surg, Dept Surg, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Dept Biostat, New York, NY 10029 USA
[5] Mt Sinai Beth Israel, Mt Sinai Hlth Syst, New York, NY USA
关键词
FINE-NEEDLE-ASPIRATION; UNDETERMINED SIGNIFICANCE; FOLLICULAR LESION; PREDICTIVE-VALUE; FOLLOW-UP; SYSTEM; CYTOPATHOLOGY; MANAGEMENT; ATYPIA; IMPACT;
D O I
10.1016/j.surg.2014.10.004
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Several recent analyses of indeterminate thyroid nodules classified as Bethesda III (follicular lesion of undetermined significance) have reported considerably greater rates of malignancy than those initially reported by the Bethesda System for Reporting Cytopathology (BSRTC). These values, however, may be overestimates owing to several sources of bias, such as referral, selection, and publication biases. Our aim was to analyze the prevalence of malignancy in Bethesda III and IV thyroid nodules in a comprehensive health system less prone to institutional referral bias, excluding incidental carcinomas, and we examine the literature for publication bias. Methods. We performed a retrospective analysis with pathologic re-review of 119 patients with Bethesda III/IV cytology undergoing surgery in a comprehensive health system by examining patient and nodule characteristics. A review of the literature was performed and analyzed for publication bias. Results. The malignancy rate in resected thyroid nodules was 13% (6/48) for Bethesda III and 28% (20/71) for Bethesda IV. There were 9 of 119 patients (8%) with incidental microcarcinomas. Age <30 years was associated with an increased risk of malignancy (odds ratio, 25.8; P = .005). Sex, nodule size, and ultrasonographic features were not associated with risk of malignancy. Analysis of the literature was indicative of publication bias for Bethesda III cohorts, with reported rates positively skewed (P = .039). Conclusion. In a comprehensive health system, the rate of malignancy in Bethesda III nodules was similar to the range reported by the BSRTC. Recent reports of greater rates of malignancy may be attributable to institutional referral patterns, operative selection, inclusion of incidental microcarcinomas, and publication bias.
引用
收藏
页码:510 / 517
页数:8
相关论文
共 50 条
  • [1] Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
    Liu, Xiaoli
    Wang, Jingjing
    Du, Wei
    Dai, Liyuan
    Fang, Qigen
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [2] Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS)
    Ho, Allen S.
    Sarti, Evan E.
    Jain, Kunal S.
    Wang, Hangjun
    Nixon, Iain J.
    Shaha, Ashok R.
    Shah, Jatin P.
    Kraus, Dennis H.
    Ghossein, Ronald
    Fish, Stephanie A.
    Wong, Richard J.
    Lin, Oscar
    Morris, Luc G. T.
    THYROID, 2014, 24 (05) : 832 - 839
  • [3] Evaluation of thyroid nodules classified as Bethesda category III on FNAC
    Garg, Shiwani
    Naik, Leena P.
    Kothari, Kanchan S.
    Fernandes, Gwendolyn C.
    Agnihotri, Mona A.
    Gokhale, Jagruti C.
    JOURNAL OF CYTOLOGY, 2017, 34 (01) : 5 - 9
  • [4] Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS): Is There a Correct Answer?
    Heller, Keith S.
    THYROID, 2014, 24 (05) : 787 - 788
  • [5] Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda Category III in an endemic region
    Kasap, Zeliha Aydin
    Kurt, Burcin
    Ozsagir, Elif
    Ercin, Mustafa Emre
    Guner, Ali
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (04) : 200 - 210
  • [6] Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate:An institutional experience
    Almahari, Sayed Ali
    Harb, Zainab
    Alshaikh, Safa
    CYTOJOURNAL, 2019, 16
  • [7] Comments on "diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region"
    Goel, Archit
    Kapatia, Gargi
    Gupta, Shruti
    Gupta, Vikasdeep
    Sidana, Shivani
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (05) : 288 - 289
  • [8] Respond to "Comments on 'Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region'"
    Kasap, Zeliha Aydin
    Kurt, Burcin
    Ozsagir, Elif
    Ercin, Mustafa Emre
    Guner, Ali
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (05) : 290 - 291
  • [9] Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS)
    Kuru, B.
    Atmaca, A.
    Tarim, I. A.
    Kefeli, M.
    Topgul, K.
    Yoruker, S.
    Elmali, M.
    Danaci, M.
    EJSO, 2016, 42 (01): : 87 - 93
  • [10] Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
    Zahid, Adnan
    Shafiq, Waqas
    Nasir, Khawaja Shehryar
    Loya, Asif
    Raza, Syed Abbas
    Sohail, Sara
    Azmat, Umal
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2021, 23